SHCBP1 a potential target in ovarian cancer growth and stemness

Background: Ovarian cancer (OC) is a prevalent form of gynecological malignancy. Abnormal expression of SHC-adaptor protein (SHC) binding and spindle-associated protein 1 (SHCBP1) is reported critical in various cancers, whereas its role in OC is unknown. Here we investigated the function of SHCBP1 in OC. Methods: The expression of SHCBP1 in OC and the survival probability of OC patients were analysed using bioinformatics. Cell growth was evaluated by Cell Counting Kit-8 (CCK-8) as well as colony formation. Cell motility was examined using the wound-healing and Transwell assays. The stemness of OC cells stemness was evaluated through sphere formation assay. Key factors associated with the wingless (Wnt)/β-catenin axis were analysed using Immunoblot. The expression of SHCBP1 was elevated in OC, and SHCBP1 was associated with the survival probability of OC patients. Results: Silencing SHCBP1 suppressed the proliferation of SKOV3 as well as A2780 cells, as well as their migration and invasion. Additionally, knockdown of SHCBP1 impaired the stemness of OC cells. Furthermore, SHCBP1 knockdown inhibited the Wnt/β-catenin axis in OC cells. Our findings indicate that silencing SHCBP1 repressed the growth, motility, and stemness of OC cells by inhibiting the Wnt/β-catenin axis. Conclusions: The abundance of SHCBP1 was enhanced in OC. Silencing SHCBP1 repressed the proliferation, migration, invasion, and stemness of OC cells by inhibiting the Wnt/β-catenin pathway. These results suggest that SHCBP1 may serve as a possible target in OC.

SHCBP1; Ovarian cancer; Growth; Stemness; Wnt/β-catenin signaling pathway

[1] Penny SM. Ovarian cancer: an overview. Radiologic Technology. 2020; 91: 561–575.

[2] An Y, Yang Q. Tumor-associated macrophage-targeted therapeutics in ovarian cancer. International Journal of Cancer. 2021; 149: 21–30.

[3] Elias KM, Guo J, Bast RC III. Early detection of ovarian cancer. Hematology/Oncology Clinics of North America. 2018; 32: 903–914.

[4] Moufarrij S, Dandapani M, Arthofer E, Gomez S, Srivastava A, Lopez-Acevedo M, et al. Epigenetic therapy for ovarian cancer: promise and progress. Clinical Epigenetics. 2019; 11: 7.

[5] Tian W, Lei N, Zhou J, Chen M, Guo R, Qin B, et al. Extracellular vesicles in ovarian cancer chemoresistance, metastasis, and immune evasion. Cell Death & Disease. 2022; 13: 64.

[6] Zeng XY, Yuan J, Wang C, Zeng D, Yong JH, Jiang XY, et al. circCELSR1 facilitates ovarian cancer proliferation and metastasis by sponging miR-598 to activate BRD4 signals. Molecular Medicine. 2020; 26: 70.

[7] Lin Y, Cai H. Biological functions and therapeutic potential of SHCBP1 in human cancer. Biomedicine & Pharmacotherapy. 2023; 160: 114362.

[8] Zhang GY, Ma ZJ, Wang L, Sun RF, Jiang XY, Yang XJ, et al. The role of Shcbp1 in signaling and disease. Current Cancer Drug Targets. 2019; 19: 854–862.

[9] Shi W, Zhang G, Ma Z, Li L, Liu M, Qin L, et al. Hyperactivation of HER2-SHCBP1-PLK1 axis promotes tumor cell mitosis and impairs trastuzumab sensitivity to gastric cancer. Nature Communications. 2021; 12: 2812.

[10] Huang Y, You M, Wu Q, Zhu W, Guo F, Lin W. SHCBP1 is a prognostic biomarker related to the tumour immune microenvironment in pan-cancer. Annals of Clinical & Laboratory Science. 2022; 52: 904–917.

[11] Xu N, Wu YP, Yin HB, Chen SH, Li XD, Xue XY, et al. SHCBP1 promotes tumor cell proliferation, migration, and invasion, and is associated with poor prostate cancer prognosis. Journal of Cancer Research and Clinical Oncology. 2020; 146: 1953–1969.

[12] Deng B, Li A, Zhu Y, Zhou Y, Fei J, Miao Y. SHCBP1 contributes to the proliferation and self‑renewal of cervical cancer cells and activation of the NF‑κB signaling pathway through EIF5A. Oncology Letters. 2023; 25: 246.

[13] Zou A, Wu A, Luo M, Zhou C, Lu Y, Yu X. SHCBP1 promotes cisplatin induced apoptosis resistance, migration and invasion through activating Wnt pathway. Life Sciences. 2019; 235: 116798.

[14] Wang S, Li Z, Zhu G, Hong L, Hu C, Wang K, et al. RNA-binding protein IGF2BP2 enhances circ_0000745 abundancy and promotes aggressiveness and stemness of ovarian cancer cells via the microRNA-3187-3p/ERBB4/PI3K/AKT axis. Journal of Ovarian Research. 2021; 14: 154.

[15] Defabianis P, Bocca N, Romano F. Prevalence and association of dental anomalies and tooth decay in Italian childhood cancer survivors. Journal of Clinical Pediatric Dentistry. 2023; 47: 81–87.

[16] O’Shea AS. Clinical staging of ovarian cancer. Methods in Molecular Biology. 2022; 2424: 3–10.

[17] Orr B, Edwards RP. Diagnosis and treatment of ovarian cancer. Hematology/Oncology Clinics of North America. 2018; 32: 943–964.

[18] Sehouli J, Grabowski JP. Surgery in recurrent ovarian cancer. Cancer. 2019; 125: 4598–4601.

[19] Bogani G, Lopez S, Mantiero M, Ducceschi M, Bosio S, Ruisi S, et al. Immunotherapy for platinum-resistant ovarian cancer. Gynecologic Oncology. 2020; 158: 484–488.

[20] Gudaityte J, Jazokaite L, Saduikyte B, Rugyte DC. The quality and continuity of systemic postoperative analgesia: a single center two-stage follow-up study. Signa Vitae. 2023; 19: 74–83.

[21] Gupta KK, Gupta VK, Naumann RW. Ovarian cancer: screening and future directions. International Journal of Gynecological Cancer. 2019; 29: 195–200.

[22] Barani M, Bilal M, Sabir F, Rahdar A, Kyzas GZ. Nanotechnology in ovarian cancer: diagnosis and treatment. Life Sciences. 2021; 266: 118914.

[23] Wang N, Zhu L, Wang L, Shen Z, Huang X. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers. Computational and Structural Biotechnology Journal. 2022; 20: 3106–3119.

[24] Li V, Vigneswaran WT. Molecular markers in guiding lung cancer diagnosis and treatment. Journal of Men’s Health. 2022; 18: 1–12.

[25] Dong YD, Yuan YL, Yu HB, Tian GJ, Li DY. SHCBP1 is a novel target and exhibits tumor‑promoting effects in gastric cancer. Oncology Research. 2019; 41: 1649–1657.

[26] Ren C, Zhou Z, Wang X, Hua X, Zou M, Zhang X. SHCBP1 promotes the progression of esophageal squamous cell carcinoma via the TGFβ pathway. Applied Immunohistochemistry & Molecular Morphology. 2021; 29: 136–143.

[27] Liu J, Xiao Q, Xiao J, Niu C, Li Y, Zhang X, et al. Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities. Signal Transduction and Targeted Therapy. 2022; 7: 3.

[28] Wang S, Xie X, Yin L, Li G, Xie J. Electroacupuncture stimulation at CV4 sites prevents breast cancer-induced osteoporosis by activating the Wnt/β-catenin signaling pathway. European Journal of Gynaecological Oncology. 2023; 44: 89–95.

[29] Cai Y, Tian J, Su Y, Shi X. MiR-506 targets polypyrimidine tract-binding protein 1 to inhibit airway inflammatory response and remodeling via mediating Wnt/β-catenin signaling pathway. Allergologia et Immunopathologia. 2023; 51: 15–24.

[30] Zhang Y, Wang X. Targeting the Wnt/β-catenin signaling pathway in cancer. Journal of Hematology & Oncology. 2020; 13: 165.

[31] Yu F, Yu C, Li F, Zuo Y, Wang Y, Yao L, et al. Wnt/β-catenin signaling in cancers and targeted therapies. Signal Transduction and Targeted Therapy. 2021; 6: 307.

[32] He S, Tang S. WNT/β-catenin signaling in the development of liver cancers. Biomedicine & Pharmacotherapy. 2020; 132: 110851.

[33] Bian J, Dannappel M, Wan C, Firestein R. Transcriptional regulation of Wnt/β-catenin pathway in colorectal cancer. Cells. 2020; 9: 2125.

[34] Ruan X, Liu A, Zhong M, Wei J, Zhang W, Rong Y, et al. Silencing LGR6 Attenuates stemness and chemoresistance via inhibiting Wnt/β-catenin signaling in ovarian cancer. Molecular Therapy Oncology. 2019; 14: 94–106.

[35] Sun Y, Pan H, He Y, Hu C, Gu Y. Functional roles of the SHCBP1 and KIF23 interaction in modulating the cell-cycle and cisplatin resistance of head and neck squamous cell carcinoma. Head & Neck. 2022; 44: 591–605.